#cipla
Cipla looks to ensure consistent drug supplies, as costs increase due to West Asia war, says MD & Global CEO
The company’s net profit at Rs ₹555 crore for the quarter under review was down 55 per cent from Rs ₹1,222 crore in the same period last year
Cipla looks to ensure consistent drug supplies, as costs increase due to West Asia war, says MD & Global CEO
The company’s net profit at Rs ₹555 crore for the quarter under review was down 55 per cent from Rs ₹1,222 crore in the same period last year
Cipla bets on fast-growing biosimilars market, to steadily add products: CEO
Cipla is developing a biosimilars pipeline, with plans to add 1-2 products yearly for the next five years. The drugmaker is investing in R&D, especially for developed markets, to build out a strong pipeline across respiratory, peptides as well as complex …